Symbiotec Pharmalab Limited (NSE:SYMBIOTEC)
India flag India · Delayed Price · Currency is INR
1,566.00
-45.30 (-2.81%)
Last updated: Nov 16, 2026, 3:29 PM IST

Symbiotec Pharmalab Statistics

Total Valuation

NSE:SYMBIOTEC has a market cap or net worth of INR 100.63 billion. The enterprise value is 103.77 billion.

Market Cap100.63B
Enterprise Value 103.77B

Important Dates

The last earnings date was Thursday, November 5, 2026.

Earnings Date Nov 5, 2026
Ex-Dividend Date n/a

Share Statistics

NSE:SYMBIOTEC has 64.26 million shares outstanding. The number of shares has increased by 9.97% in one year.

Current Share Class 64.26M
Shares Outstanding 64.26M
Shares Change (YoY) +9.97%
Shares Change (QoQ) +0.53%
Owned by Insiders (%) 12.93%
Owned by Institutions (%) 42.79%
Float 25.98M

Valuation Ratios

The trailing PE ratio is 75.90 and the forward PE ratio is 61.23. NSE:SYMBIOTEC's PEG ratio is 1.66.

PE Ratio 75.90
Forward PE 61.23
PS Ratio 10.39
PB Ratio 7.39
P/TBV Ratio 7.39
P/FCF Ratio n/a
P/OCF Ratio 106.08
PEG Ratio 1.66
Financial Ratio History

Enterprise Valuation

EV / Earnings 82.01
EV / Sales 10.71
EV / EBITDA 38.59
EV / EBIT 53.76
EV / FCF n/a

Financial Position

The company has a current ratio of 1.36, with a Debt / Equity ratio of 0.25.

Current Ratio 1.36
Quick Ratio 0.60
Debt / Equity 0.25
Debt / EBITDA 1.25
Debt / FCF n/a
Interest Coverage 7.96

Financial Efficiency

Return on Equity (ROE) n/a
Return on Assets (ROA) n/a
Return on Invested Capital (ROIC) 9.73%
Return on Capital Employed (ROCE) 12.34%
Weighted Average Cost of Capital (WACC) n/a
Revenue Per Employee 5.06M
Profits Per Employee 660,715
Employee Count1,915
Asset Turnover n/a
Inventory Turnover n/a

Taxes

In the past 12 months, NSE:SYMBIOTEC has paid 301.03 million in taxes.

Income Tax 301.03M
Effective Tax Rate 19.22%

Stock Price Statistics

Beta (5Y) n/a
52-Week Price Change n/a
50-Day Moving Average 1,215.38
200-Day Moving Average n/a
Relative Strength Index (RSI) 68.08
Average Volume (20 Days) 917,982

Short Selling Information

Short Interest n/a
Short Previous Month n/a
Short % of Shares Out n/a
Short % of Float n/a
Short Ratio (days to cover) n/a

Income Statement

In the last 12 months, NSE:SYMBIOTEC had revenue of INR 9.69 billion and earned 1.27 billion in profits. Earnings per share was 20.63.

Revenue9.69B
Gross Profit 6.16B
Operating Income 1.93B
Pretax Income 1.57B
Net Income 1.27B
EBITDA 2.68B
EBIT 1.93B
Earnings Per Share (EPS) 20.63
Full Income Statement

Balance Sheet

The company has 217.66 million in cash and 3.36 billion in debt, with a net cash position of -3.14 billion or -48.89 per share.

Cash & Cash Equivalents 217.66M
Total Debt 3.36B
Net Cash -3.14B
Net Cash Per Share -48.89
Equity (Book Value) 13.61B
Book Value Per Share 215.75
Working Capital 1.72B
Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was 948.61 million and capital expenditures -2.29 billion, giving a free cash flow of -1.34 billion.

Operating Cash Flow 948.61M
Capital Expenditures -2.29B
Depreciation & Amortization 745.15M
Net Borrowing -1.83B
Free Cash Flow -1.34B
FCF Per Share -20.89
Full Cash Flow Statement

Margins

Gross margin is 63.65%, with operating and profit margins of 19.93% and 13.06%.

Gross Margin 63.65%
Operating Margin 19.93%
Pretax Margin 16.17%
Profit Margin 13.06%
EBITDA Margin 27.62%
EBIT Margin 19.93%
FCF Margin n/a

Dividends & Yields

NSE:SYMBIOTEC does not appear to pay any dividends at this time.

Dividend Per Share n/a
Dividend Yield n/a
Dividend Growth (YoY) n/a
Years of Dividend Growth n/a
Payout Ratio n/a
FCF Payout Ratio n/a
Buyback Yield -9.97%
Shareholder Yield -9.97%
Earnings Yield 1.32%
FCF Yield -1.33%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value n/a
Lynch Upside n/a
Graham Number
Graham Upside
Graham Formula Value n/a
Graham Formula Upside n/a

Analyst Forecast

The average price target for NSE:SYMBIOTEC is 1,654.00, which is 5.62% higher than the current price. The consensus rating is "Strong Buy".

Price Target 1,654.00
Price Target Difference 5.62%
Analyst Consensus Strong Buy
Analyst Count 3
Revenue Growth Forecast (3Y) 27.63%
EPS Growth Forecast (3Y) n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date n/a
Split Type n/a
Split Ratio n/a

Scores

Altman Z-Score n/a
Piotroski F-Score 5